19 results
Thumbnail

D1.396 - Drug hypersensitivity reactions in paediatric patients pre and post-liver transplant: a single-center study

Thumbnail

D1.394 - Functional AOC1 variants associated with reduced diamine oxidase activity mimicking multiple drug hypersensitivity and mast cell disorders

Thumbnail

D1.397 - Successfull rapid drug desensitization to cemiplimab in a patient with lung squamous cell carcinoma

Thumbnail

D1.398 - Safety Outcomes and Predictors of Clinically Significant Reactions in Positive Drug Provocation Tests: A 10-Year Tertiary-Center Cohort

Thumbnail

D1.399 - Selective IgE Mediated Anaphylaxis to Gadobutrol and type I Kounis with tolerance to Gadoxetate Disodium

Thumbnail

D1.400 - Omalizumab premedication improves ferric carboxymaltose desensitization outcomes: A Case Report

Thumbnail

D1.401 - Progression from Immediate to Delayed Hypersensitivity: A Rare Case of Iodixanol-Induced Acute Generalised Exanthematous Pustulosis

Thumbnail

D1.402 - Angiotensin-Converting Enzyme Inhibitor–Induced Bradykinin-Mediated Angioedema: Three Cases of Sustained Remission Following Definitive Discontinuation and the Critical Role of the Prescribing Physician

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)

Thumbnail

D1.441 - A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases

Thumbnail

D1.444 - Dual Blockade of IL22 and IL23 with a bispecific antibody: A Promising Strategy for the Treatment of Psoriasis and Other Autoimmune Skin Disorders